Media on Resveratrol & Anti-aging

June 2011
European Journal of Pharmacology
According to new study, Resveratrol helps protect you from heart disease, namely Atherosclerosis

Oct 2010
Resveratrol displays metabolic benefits for obesity
Writing in the International Journal for Obesity researchers from the University of Aarhus in Denmark suggest that resveratrol has anti-inflammatory effects on adipokine expression and secretion in human fat tissue.
Sept 2010
The End of Aging , RTE Programme, Professor Rose Anne Kenny examines the social , biological and scientific changes that is bringing about a change to our life span
Sept 2010
Vitamin B could delay Alzheimers
July 2010
Possible treatment for alzheimers disease discovered
June 2010
TILDA , The Irish longituDinal study on Ageing , is the most detailed study of ageing ever undertaken in Ireland
June 2010
Science News : Resveratrol shows activity against insulin resistance
May 2010
Daily Mail (UK) report ,
A revolutionary jab that could prevent and treat breast cancer has been developed
April 2010
Science Daily reported that researchers at John Hopkins say they have discovered the way in which red wine consumption may protect the brain from damage following a stroke.

Feb 2010
Fitness Magazine,  article titled, Resveratrol: "The New Weight-loss Supplement"
written by Richard Laliberte highlights some findings regarding the potential fitness benefits of resveratrol.

1st Nov 2009
“To Age or Not to Age”, a riveting new film by Robert Pappas which tracks the pioneers in the field of anti-aging research. It also provides interviews with many key players in the resveratrol and anti-aging debate such as David Sinclair, Leonard Guarente, Cynthia Kenyon, Aubrey de Grey and Christoph Westphal.
The Nationwide Premier of this documentary in the USA took place on the 11Th Feb 2010. For more info check out http://toageornottoage.com
 

0ct 20th ,2009
Science Daily reported – A naturally produced molecule called Resveratrol ,found in the skin of red grapes, has been shown to lower insulin levels in mice when injected directly into the brain, even when the animals ate high-fat diet.

Oct 9th ,2009
Science Daily reported – Resveratrol has been shown to improve diabetes when delivered orally to rodents. Until now, however, little has been known about how these benefical changes are mediated in the body. A new study accepted for publication in Endocrinology, a journal of The Endocrine Society, shows that the brain plays a key role in mediating resveratrol,s anti-diabetic actions, potentially paving the way for future orally-delivered diabetes medications that target the brain.

Sept 2009
At a conference on aging held at Harvard Medical School , Get Science News which is part of “The New York Times” included the following within their report.

The heavyweight at the conference was Sirtris Pharmaceuticals. Both David Sinclair and Christoph Westphal are co-founders of Sitris Pharmaceuticals.The company is developing drugs that mimic resveratrol. Resveratrol has been found to activate proteins called sirtuins, from which the company derives its name. Activation of sirtuins is thought to help the body ride out famines. Mice and rats put on a diet with 30 percent fewer calories can live up to 40 percent longer. They seem to do so by avoiding the usual degenerative diseases of aging and so gain not just longer life but more time in good health.Sirtris’s researchers think that drugs that activate sirtuins mimic this process, strengthening the body’s resistance to the diseases of aging.

In mice,sirtuin activators are effective against lung and colon cancer, melanoma, lymphoma, Type 2 diabetes, cardiovascular diseases and Alzheimer,s disease, said David Sinclair.The drugs reduce inflammation, and if they have the same effects in people could help combat many diseases that have an inflammatory component, like irritable bowel syndrome and glaucoma. Any sirtuin activator that averted all these diseases in people would be a remarkable drug. Sirtris,s senior director of corporate development, Brian Gallagher said at the conference that four active clinical trials are under way.